MA38391A1 - Dérivés de pyridinyl et triazolone pyridinyl de fusion - Google Patents

Dérivés de pyridinyl et triazolone pyridinyl de fusion

Info

Publication number
MA38391A1
MA38391A1 MA38391A MA38391A MA38391A1 MA 38391 A1 MA38391 A1 MA 38391A1 MA 38391 A MA38391 A MA 38391A MA 38391 A MA38391 A MA 38391A MA 38391 A1 MA38391 A1 MA 38391A1
Authority
MA
Morocco
Prior art keywords
pyridinyl
compounds
formula
triazolone
fusion
Prior art date
Application number
MA38391A
Other languages
English (en)
Other versions
MA38391B1 (fr
Inventor
John David Lawson
Mark Sabat
Nicholas Scorah
Christopher Smith
Phong H Vu
Haixia Wang
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of MA38391A1 publication Critical patent/MA38391A1/fr
Publication of MA38391B1 publication Critical patent/MA38391B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

L'invention concerne des composés de formule 1 ou des sels pharmaceutiquement acceptables de ceux-ci, dans la formule, r1, r2, r3, et r4 sont tels que définis dans la description. Cette invention concerne également des matières et des procédés permettant de préparer les composés de formule 1, des compositions pharmaceutiques contenant ces composés, ainsi que leur utilisation pour traiter des réactions d'hypersensibilité de type i, des maladies auto-immunes, des troubles inflammatoires, le cancer, des troubles proliférants bénins, et d'autres états associés à la tyrosine kinase de bruton (btk).
MA38391A 2013-03-11 2014-03-10 Dérivés de pyridinyl et triazolone pyridinyl de fusion MA38391B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776445P 2013-03-11 2013-03-11
PCT/US2014/022801 WO2014164558A1 (fr) 2013-03-11 2014-03-10 Dérivés de pyridinyl et triazolone pyridinyl de fusion

Publications (2)

Publication Number Publication Date
MA38391A1 true MA38391A1 (fr) 2018-01-31
MA38391B1 MA38391B1 (fr) 2018-09-28

Family

ID=50543655

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38391A MA38391B1 (fr) 2013-03-11 2014-03-10 Dérivés de pyridinyl et triazolone pyridinyl de fusion

Country Status (42)

Country Link
US (4) US9402841B2 (fr)
EP (2) EP2970202B1 (fr)
JP (2) JP6271700B2 (fr)
KR (1) KR102300612B1 (fr)
CN (1) CN105121427B (fr)
AP (1) AP2015008646A0 (fr)
AR (1) AR095198A1 (fr)
AU (1) AU2014249248B2 (fr)
BR (1) BR112015020264B1 (fr)
CA (1) CA2899948C (fr)
CL (1) CL2015002370A1 (fr)
CR (1) CR20150470A (fr)
CY (1) CY1119356T1 (fr)
DK (1) DK2970202T3 (fr)
DO (1) DOP2015000184A (fr)
EA (1) EA028584B1 (fr)
EC (1) ECSP15042779A (fr)
ES (2) ES2714166T3 (fr)
GE (1) GEP201706778B (fr)
HK (2) HK1220183A1 (fr)
HR (1) HRP20170622T1 (fr)
HU (1) HUE032720T2 (fr)
IL (1) IL240353B (fr)
JO (1) JO3377B1 (fr)
LT (1) LT2970202T (fr)
MA (1) MA38391B1 (fr)
ME (1) ME02693B (fr)
MX (1) MX364527B (fr)
MY (1) MY183927A (fr)
PE (1) PE20151889A1 (fr)
PH (1) PH12015502046A1 (fr)
PL (1) PL2970202T3 (fr)
PT (1) PT2970202T (fr)
RS (1) RS55879B1 (fr)
SG (1) SG11201506112QA (fr)
SI (1) SI2970202T1 (fr)
TN (1) TN2015000342A1 (fr)
TW (1) TWI637950B (fr)
UA (1) UA114944C2 (fr)
UY (1) UY35376A (fr)
WO (1) WO2014164558A1 (fr)
ZA (1) ZA201505996B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102203990B1 (ko) 2012-09-10 2021-01-18 프린시피아 바이오파마, 인코퍼레이티드 키나제 저해제로서의 피라졸로피리미딘 화합물
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
PT3107544T (pt) 2014-02-21 2021-01-05 Principia Biopharma Inc Sais e forma sólida de um inibidor de btk
CN104447530A (zh) * 2014-12-11 2015-03-25 苏州欧凯医药技术有限公司 4-甲基-2,6-二羧基吡啶的制备方法
EP3233103B1 (fr) * 2014-12-18 2020-10-14 Principia Biopharma Inc. Traitement de le pemphigus
WO2016210165A1 (fr) 2015-06-24 2016-12-29 Principia Biopharma Inc. Inhibiteurs de la tyrosine kinase
MX2018007721A (es) * 2015-12-24 2018-08-15 Takeda Pharmaceuticals Co Cocristal, metodo de produccion del mismo, y medicamento que contiene el cocristal.
PL3402503T3 (pl) * 2016-01-13 2021-04-19 Acerta Pharma B.V. Kombinacje terapeutyczne antyfolianu oraz inhibitora btk
US20190105407A1 (en) * 2016-03-31 2019-04-11 Takeda Pharmaceutical Company Limited Isoquinolinyl triazolone complexes
CN115054586A (zh) 2016-06-29 2022-09-16 普林斯匹亚生物制药公司 改性的释放制剂
KR20210038877A (ko) 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
WO2020188015A1 (fr) 2019-03-21 2020-09-24 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
WO2020204602A1 (fr) * 2019-04-02 2020-10-08 연세대학교 산학협력단 Nouveau composé et composition pour la prévention ou le traitement de maladies respiratoires comprenant celui-ci comme principe actif
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CA3185469A1 (fr) 2020-08-14 2022-02-17 Novartis Ag Derives de spiropiperidinyle substitues par heteroaryle et leurs utilisations pharmaceutiques
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5733849A (en) * 1996-03-15 1998-03-31 Rohm And Haas Company Halopyridyl triazolinone herbicides and herbicidal use thereof
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP2002512216A (ja) 1998-04-17 2002-04-23 パーカー ヒューズ インスティテュート Ｂｔｋインヒビターならびにその同定方法および使用方法
CA2422377C (fr) * 2000-09-15 2010-04-13 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteine kinase
PT1347971E (pt) 2000-12-21 2006-06-30 Bristol Myers Squibb Co Inibidores tiazolilicos de tirosina-cinases da familia tec
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
KR20080098490A (ko) 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
US8053456B2 (en) * 2006-05-25 2011-11-08 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
CA2653758A1 (fr) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Derives tetraline et indane et leurs utilisations
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
NZ601278A (en) 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
CA3143428A1 (fr) 2007-03-28 2008-10-09 Pharmacyclics Llc 8-amino-3-substitute-imidazo[1,5-a]pyrazine et utilisation connexe comme inhibiteurs de tyrosine kinase de bruton
WO2009077334A1 (fr) 2007-12-14 2009-06-25 F. Hoffmann-La Roche Ag Dérivés innovants d'imidazo[1,2-a]pyridine et d'imidazo[1,2-b]pyridazine
NZ586916A (en) 2008-02-05 2012-06-29 Hoffmann La Roche Novel pyridinones and pyridazinones
CA2728016C (fr) 2008-06-24 2017-02-28 F. Hoffmann-La Roche Ag Nouvelles pyridine-2-ones et pyridazine-3-ones substituees
JP5490789B2 (ja) 2008-07-02 2014-05-14 エフ．ホフマン−ラ ロシュ アーゲー キナーゼ阻害剤としての新規なフェニルピラジノン
ES2552681T3 (es) 2008-07-15 2015-12-01 F. Hoffmann-La Roche Ag Nuevas fenil-imidazopiridinas y piridazinas
EP2365970B1 (fr) 2008-11-12 2018-03-21 Gilead Connecticut, Inc. Pyridazinones et leur utilisation comme inhibiteurs btk
WO2010068810A2 (fr) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amides substitués, et leurs procédés de production et d'utilisation
WO2010068788A1 (fr) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amides hétérocycliques en tant qu'inhibiteurs de la btk
JP2013526546A (ja) 2010-05-13 2013-06-24 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物
WO2011153553A2 (fr) 2010-06-04 2011-12-08 The Regents Of The University Of California Méthodes et compositions pour l'inhibition de kinases
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
JP5947307B2 (ja) 2010-10-20 2016-07-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３調節因子としての置換６−アミノ−ニコチンアミド
EP2637816A4 (fr) 2010-11-10 2017-07-26 Stc.Unm Synthèse par réduction/expansion en aérosol (a-res) pour particules de métal à valence zéro
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج

Also Published As

Publication number Publication date
US20180015083A1 (en) 2018-01-18
JP6462842B2 (ja) 2019-01-30
AR095198A1 (es) 2015-09-30
EP3235814A1 (fr) 2017-10-25
HK1245256B (zh) 2019-09-27
EP2970202A1 (fr) 2016-01-20
SG11201506112QA (en) 2015-09-29
DOP2015000184A (es) 2015-11-30
RS55879B1 (sr) 2017-08-31
CA2899948A1 (fr) 2014-10-09
EA201591686A1 (ru) 2015-12-30
US20140256734A1 (en) 2014-09-11
NZ710852A (en) 2020-12-18
ME02693B (fr) 2017-10-20
EA028584B1 (ru) 2017-12-29
AU2014249248A1 (en) 2015-08-20
BR112015020264B1 (pt) 2021-03-02
PL2970202T3 (pl) 2017-08-31
EP3235814B1 (fr) 2018-12-12
MX2015011533A (es) 2016-02-03
TWI637950B (zh) 2018-10-11
JP2018076357A (ja) 2018-05-17
PE20151889A1 (es) 2015-12-26
ES2624439T3 (es) 2017-07-14
HUE032720T2 (en) 2017-10-30
ECSP15042779A (es) 2017-08-31
CA2899948C (fr) 2021-11-16
GEP201706778B (en) 2017-11-27
CY1119356T1 (el) 2018-02-14
EP2970202B1 (fr) 2017-02-01
ZA201505996B (en) 2016-11-30
DK2970202T3 (en) 2017-05-08
KR20150126687A (ko) 2015-11-12
CR20150470A (es) 2016-01-11
UA114944C2 (uk) 2017-08-28
CN105121427B (zh) 2018-04-10
US9402841B2 (en) 2016-08-02
ES2714166T3 (es) 2019-05-27
US20190224190A1 (en) 2019-07-25
CN105121427A (zh) 2015-12-02
TN2015000342A1 (en) 2017-01-03
AU2014249248B2 (en) 2017-08-17
WO2014164558A1 (fr) 2014-10-09
BR112015020264A2 (pt) 2017-07-18
MY183927A (en) 2021-03-17
US10307414B2 (en) 2019-06-04
HK1220183A1 (zh) 2017-04-28
TW201522328A (zh) 2015-06-16
JP2016512515A (ja) 2016-04-28
JP6271700B2 (ja) 2018-01-31
LT2970202T (lt) 2017-06-12
UY35376A (es) 2014-10-31
PH12015502046B1 (en) 2016-01-18
IL240353A0 (en) 2015-09-24
MX364527B (es) 2019-04-30
JO3377B1 (ar) 2019-03-13
CL2015002370A1 (es) 2016-03-11
US20160310483A1 (en) 2016-10-27
PH12015502046A1 (en) 2016-01-18
AP2015008646A0 (en) 2015-08-31
HRP20170622T1 (hr) 2017-06-30
PT2970202T (pt) 2017-05-03
MA38391B1 (fr) 2018-09-28
US9801872B2 (en) 2017-10-31
IL240353B (en) 2018-11-29
KR102300612B1 (ko) 2021-09-09
SI2970202T1 (sl) 2017-07-31

Similar Documents

Publication Publication Date Title
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA47079B1 (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA35348B1 (fr) 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA38138A1 (fr) Dérivés inédits de quinolone
TN2014000537A1 (fr) 4-(amino-substitue) – 7h-pyrrolo [2, 3-d] pyrimidines nouvelles servant d'inhibiteurs de lrrk2
MA41179A (fr) Composés inhibiteurs de parg
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA37831B1 (fr) Dérivés d'azaindole agissant comme inhibiteur de pi3k
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
MA44948A1 (fr) Inhibiteurs de bace 1
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA46268A (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma